Ipca Laboratories Limited (IPCALAB.BO)
INR 1363.95
(4.85%)
INR 1363.95
(4.85%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 11.41 Billion INR | 410.93% |
| 2022 | 2.23 Billion INR | -58.01% |
| 2021 | 5.32 Billion INR | 435.13% |
| 2020 | 994.2 Million INR | -77.52% |
| 2019 | 4.42 Billion INR | 140.66% |
| 2018 | 1.83 Billion INR | -61.58% |
| 2017 | 4.78 Billion INR | -30.31% |
| 2016 | 6.86 Billion INR | -1.72% |
| 2015 | 6.98 Billion INR | -36.97% |
| 2014 | 11.07 Billion INR | 109.7% |
| 2013 | 5.28 Billion INR | -5.72% |
| 2012 | 5.6 Billion INR | -5.08% |
| 2011 | 5.9 Billion INR | 31.88% |
| 2010 | 4.47 Billion INR | 0.88% |
| 2009 | 4.43 Billion INR | -1.09% |
| 2008 | 4.48 Billion INR | 30.56% |
| 2007 | 3.43 Billion INR | 50.16% |
| 2006 | 2.28 Billion INR | 19.54% |
| 2005 | 1.91 Billion INR | -11.27% |
| 2004 | 2.15 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 11.41 Billion INR | 410.93% |
| 2023 Q3 | 9.34 Billion INR | -39.87% |
| 2023 Q4 | 11.41 Billion INR | 22.21% |
| 2023 Q1 | 21.76 Billion INR | 874.01% |
| 2023 Q2 | 15.53 Billion INR | -28.61% |
| 2022 Q3 | 12.96 Billion INR | 273.79% |
| 2022 Q4 | 2.23 Billion INR | -82.77% |
| 2022 Q1 | 13.6 Billion INR | 155.67% |
| 2022 FY | 2.23 Billion INR | -58.01% |
| 2022 Q2 | 3.46 Billion INR | -74.5% |
| 2021 Q4 | 5.32 Billion INR | -45.1% |
| 2021 FY | 5.32 Billion INR | 435.13% |
| 2021 Q2 | 1.49 Billion INR | -80.32% |
| 2021 Q3 | 9.69 Billion INR | 549.85% |
| 2021 Q1 | 7.57 Billion INR | 662.06% |
| 2020 Q1 | 4.17 Billion INR | -5.52% |
| 2020 FY | 994.2 Million INR | -77.52% |
| 2020 Q4 | 994.2 Million INR | -90.36% |
| 2020 Q3 | 10.31 Billion INR | 798.95% |
| 2020 Q2 | 1.14 Billion INR | -72.55% |
| 2019 Q1 | 3.71 Billion INR | 102.19% |
| 2019 Q4 | 4.42 Billion INR | -1.85% |
| 2019 Q3 | 4.5 Billion INR | 169.39% |
| 2019 Q2 | 1.67 Billion INR | -54.98% |
| 2019 FY | 4.42 Billion INR | 140.66% |
| 2018 Q4 | 1.83 Billion INR | 0.0% |
| 2018 Q1 | 2.18 Billion INR | 0.0% |
| 2018 FY | 1.83 Billion INR | -61.58% |
| 2017 FY | 4.78 Billion INR | -30.31% |
| 2016 FY | 6.86 Billion INR | -1.72% |
| 2015 FY | 6.98 Billion INR | -36.97% |
| 2014 FY | 11.07 Billion INR | 109.7% |
| 2013 FY | 5.28 Billion INR | -5.72% |
| 2012 FY | 5.6 Billion INR | -5.08% |
| 2011 FY | 5.9 Billion INR | 31.88% |
| 2010 FY | 4.47 Billion INR | 0.88% |
| 2009 FY | 4.43 Billion INR | -1.09% |
| 2008 FY | 4.48 Billion INR | 30.56% |
| 2007 FY | 3.43 Billion INR | 50.16% |
| 2006 FY | 2.28 Billion INR | 19.54% |
| 2005 FY | 1.91 Billion INR | -11.27% |
| 2004 FY | 2.15 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | -195.279% |
| Aurobindo Pharma Limited | 3.69 Billion INR | -209.079% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 501.568% |
| Granules India Limited | 9.28 Billion INR | -22.919% |
| Indoco Remedies Limited | 6.47 Billion INR | -76.261% |
| Achyut Healthcare Limited | -3.74 Million INR | 304830.379% |
| Ajanta Pharma Limited | -954.9 Million INR | 1295.434% |
| Alkem Laboratories Limited | -1.6 Billion INR | 809.283% |
| Alpa Laboratories Limited | 35.36 Million INR | -32180.067% |
| Brooks Laboratories Limited | 49.48 Million INR | -22968.0% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 327.737% |
| Bajaj HealthCare Limited | 3.29 Billion INR | -246.025% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 1085.98% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 11.599% |
| Eris Lifesciences Limited | 13.8 Billion INR | 17.319% |
| FDC Limited | -57.75 Million INR | 19865.896% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 366.383% |
| Gufic Biosciences Limited | 3.19 Billion INR | -257.36% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 374.863% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 921.279% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -490.567% |
| Lasa Supergenerics Limited | 205.79 Million INR | -5446.771% |
| Laurus Labs Limited | 24.38 Billion INR | 53.187% |
| Lupin Limited | 17.19 Billion INR | 33.603% |
| Mankind Pharma Limited | -9.9 Billion INR | 215.212% |
| Medicamen Biotech Limited | 160.31 Million INR | -7020.437% |
| Medico Remedies Limited | 78.67 Million INR | -14408.942% |
| Megasoft Limited | 1.28 Billion INR | -787.961% |
| NATCO Pharma Limited | -5.81 Billion INR | 296.239% |
| Piramal Pharma Limited | 42.27 Billion INR | 72.998% |
| RPG Life Sciences Limited | -364.7 Million INR | 3230.025% |
| Sigachi Industries Limited | 859.94 Million INR | -1227.428% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 115.752% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -7773.855% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -24602.344% |
| Unichem Laboratories Limited | 931.91 Million INR | -1124.917% |
| Wanbury Limited | 1.1 Billion INR | -932.232% |
| Windlas Biotech Limited | -273.04 Million INR | 4280.779% |
| ZIM Laboratories Limited | 983.6 Million INR | -1060.548% |
| Zydus Lifesciences Limited | 3.91 Billion INR | -191.8% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 1312.062% |
| Divi's Laboratories Limited | -39.77 Billion INR | 128.703% |
| Hester Biosciences Limited | 2.29 Billion INR | -398.319% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 586.167% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 4688.25% |
| Bal Pharma Limited | 1.26 Billion INR | -803.415% |
| Strides Pharma Science Limited | 23.25 Billion INR | 50.917% |
| Venus Remedies Limited | -267.7 Million INR | 4364.176% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -337.046% |
| Nectar Lifesciences Limited | 6.15 Billion INR | -85.393% |
| Shilpa Medicare Limited | 9.06 Billion INR | -25.863% |
| Aarti Drugs Limited | 5.54 Billion INR | -105.739% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 1136.52% |
| Suven Life Sciences Limited | -1.63 Billion INR | 799.162% |
| Ind-Swift Limited | 9.5 Billion INR | -20.051% |
| Valiant Laboratories Limited | -295.03 Million INR | 3969.14% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -304.622% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | -13.822% |
| Themis Medicare Limited | 764.96 Million INR | -1392.257% |
| Hikal Limited | 7.96 Billion INR | -43.281% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 64.137% |
| Sequent Scientific Limited | 4.17 Billion INR | -173.18% |
| Novartis India Limited | -5.89 Billion INR | 293.77% |
| Wockhardt Limited | 18.27 Billion INR | 37.519% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 57.834% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 61984.419% |
| Neuland Laboratories Limited | -214.05 Million INR | 5432.76% |
| Morepen Laboratories Limited | -231.17 Million INR | 5037.926% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -9409.576% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -1069.817% |